Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proteogenomic insights suggest druggable pathways in endometrial carcinoma.
Dou Y, Katsnelson L, Gritsenko MA, Hu Y, Reva B, Hong R, Wang YT, Kolodziejczak I, Lu RJ, Tsai CF, Bu W, Liu W, Guo X, An E, Arend RC, Bavarva J, Chen L, Chu RK, Czekański A, Davoli T, Demicco EG, DeLair D, Devereaux K, Dhanasekaran SM, Dottino P, Dover B, Fillmore TL, Foxall M, Hermann CE, Hiltke T, Hostetter G, Jędryka M, Jewell SD, Johnson I, Kahn AG, Ku AT, Kumar-Sinha C, Kurzawa P, Lazar AJ, Lazcano R, Lei JT, Li Y, Liao Y, Lih TM, Lin TT, Martignetti JA, Masand RP, Matkowski R, McKerrow W, Mesri M, Monroe ME, Moon J, Moore RJ, Nestor MD, Newton C, Omelchenko T, Omenn GS, Payne SH, Petyuk VA, Robles AI, Rodriguez H, Ruggles KV, Rykunov D, Savage SR, Schepmoes AA, Shi T, Shi Z, Tan J, Taylor M, Thiagarajan M, Wang JM, Weitz KK, Wen B, Williams CM, Wu Y, Wyczalkowski MA, Yi X, Zhang X, Zhao R, Mutch D, Chinnaiyan AM, Smith RD, Nesvizhskii AI, Wang P, Wiznerowicz M, Ding L, Mani DR, Zhang H, Anderson ML, Rodland KD, Zhang B, Liu T, Fenyö D; Clinical Proteomic Tumor Analysis Consortium. Dou Y, et al. Among authors: lazcano r. Cancer Cell. 2023 Sep 11;41(9):1586-1605.e15. doi: 10.1016/j.ccell.2023.07.007. Epub 2023 Aug 10. Cancer Cell. 2023. PMID: 37567170 Free article.
Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time.
Nguyen TDT, Wang Y, Bui TN, Lazcano R, Ingram DR, Yi M, Vakulabharanam V, Luo L, Pina MA, Karakas C, Li M, Kettner NM, Somaiah N, Hougton PJ, Mawlawi O, Lazar AJ, Hunt KK, Keyomarsi K. Nguyen TDT, et al. Among authors: lazcano r. Cancer Res. 2023 Mar 15;83(6):939-955. doi: 10.1158/0008-5472.CAN-22-2258. Cancer Res. 2023. PMID: 36603130 Free PMC article.
Targeting the Molecular and Immunologic Features of Leiomyosarcoma.
Cope BM, Traweek RS, Lazcano R, Keung EZ, Lazar AJ, Roland CL, Nassif EF. Cope BM, et al. Among authors: lazcano r. Cancers (Basel). 2023 Mar 31;15(7):2099. doi: 10.3390/cancers15072099. Cancers (Basel). 2023. PMID: 37046760 Free PMC article. Review.
Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin.
Liang WW, Lu RJ, Jayasinghe RG, Foltz SM, Porta-Pardo E, Geffen Y, Wendl MC, Lazcano R, Kolodziejczak I, Song Y, Govindan A, Demicco EG, Li X, Li Y, Sethuraman S, Payne SH, Fenyö D, Rodriguez H, Wiznerowicz M, Shen H, Mani DR, Rodland KD, Lazar AJ, Robles AI, Ding L; Clinical Proteomic Tumor Analysis Consortium. Liang WW, et al. Among authors: lazcano r. Cancer Cell. 2023 Sep 11;41(9):1567-1585.e7. doi: 10.1016/j.ccell.2023.07.013. Epub 2023 Aug 14. Cancer Cell. 2023. PMID: 37582362 Free article.
Deep learning integrates histopathology and proteogenomics at a pan-cancer level.
Wang JM, Hong R, Demicco EG, Tan J, Lazcano R, Moreira AL, Li Y, Calinawan A, Razavian N, Schraink T, Gillette MA, Omenn GS, An E, Rodriguez H, Tsirigos A, Ruggles KV, Ding L, Robles AI, Mani DR, Rodland KD, Lazar AJ, Liu W, Fenyö D; Clinical Proteomic Tumor Analysis Consortium. Wang JM, et al. Among authors: lazcano r. Cell Rep Med. 2023 Sep 19;4(9):101173. doi: 10.1016/j.xcrm.2023.101173. Epub 2023 Aug 14. Cell Rep Med. 2023. PMID: 37582371 Free PMC article.
Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy.
Terranova CJ, Tang M, Maitituoheti M, Raman AT, Ghosh AK, Schulz J, Amin SB, Orouji E, Tomczak K, Sarkar S, Oba J, Creasy C, Wu CJ, Khan S, Lazcano R, Wani K, Singh A, Barrodia P, Zhao D, Chen K, Haydu LE, Wang WL, Lazar AJ, Woodman SE, Bernatchez C, Rai K. Terranova CJ, et al. Among authors: lazcano r. Cell Rep. 2021 Jul 20;36(3):109410. doi: 10.1016/j.celrep.2021.109410. Cell Rep. 2021. PMID: 34289358 Free PMC article.
Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma.
Wang Y, Tian X, Zhang W, Zhang Z, Lazcano R, Hingorani P, Roth ME, Gill JD, Harrison DJ, Xu Z, Jusu S, Kannan S, Wang J, Lazar AJ, Earley EJ, Erickson SW, Gelb T, Huxley P, Lahdenranta J, Mudd G, Kurmasheva RT, Houghton PJ, Smith MA, Kolb EA, Gorlick R. Wang Y, et al. Among authors: lazcano r. Mol Cancer Ther. 2022 Jun 1;21(6):903-913. doi: 10.1158/1535-7163.MCT-21-0836. Mol Cancer Ther. 2022. PMID: 35312779 Free PMC article.
Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma.
Beird HC, Wu CC, Nakazawa M, Ingram D, Daniele JR, Lazcano R, Little L, Davies C, Daw NC, Wani K, Wang WL, Song X, Gumbs C, Zhang J, Rubin B, Conley A, Flanagan AM, Lazar AJ, Futreal PA. Beird HC, et al. Among authors: lazcano r. HGG Adv. 2023 Jul 19;4(4):100224. doi: 10.1016/j.xhgg.2023.100224. eCollection 2023 Oct 12. HGG Adv. 2023. PMID: 37593416 Free PMC article.
38 results